title: IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine.
abstract: Interleukin-27 (IL-27) is a member of IL-6/IL-12 cytokine family which possesses pro- and anti-inflammatory properties and participates in the pathogenesis of various autoimmune diseases. In our case-control study, plasma was collected from healthy subjects as control group (n = 40) and patients with relapsing-remitting multiple sclerosis (RRMS) (n = 40), including new identified cases without treatment (n = 12) and those treated with Interferon beta (IFN-β) (n = 28). The plasma level of IL-27 was assessed by ELISA method. Our results indicated that plasma level of IL-27 in MS patients increased significantly compared to the control subjects (P = 0.027). Furthermore, after parting case group into the two sub-groups, results revealed a significant difference of IL-27 plasma levels between control group and treated patients (P < 0.001), but not about that of between healthy subjects and untreated MS patients (P = 0.259). Also, mean levels of IL-27 in treated and untreated patients showed a significant difference (P = 0.007). These results demonstrate the possible modulation of IL-27 during autoimmune disease in human which may suggest the suppressive or therapeutic role of IL-27 on inflammatory diseases.
authors.affiliation: a Departments of Genetics and Molecular Biology, School of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran.|b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.
authors.forename: Shamsi
authors.initials: S
authors.lastname: Naderi
authors.affiliation: a Departments of Genetics and Molecular Biology, School of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran.|b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Hejazi
authors.affiliation: b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|c Applied Physiology Research Center, Isfahan University of Medical Sciences , Isfahan , Iran.
authors.forename: Mansour
authors.initials: M
authors.lastname: Shajarian
authors.affiliation: b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|d Department of Immunology, School of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran.
authors.forename: Fereshteh
authors.initials: F
authors.lastname: Alsahebfosoul
authors.affiliation: b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|e Department of Neurology, School of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran.
authors.forename: Masoud
authors.initials: M
authors.lastname: Etemadifar
authors.affiliation: b Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|d Department of Immunology, School of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran.
authors.forename: Nahid
authors.initials: N
authors.lastname: Sedaghat
mesh_terms: D000293:Adolescent; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D064094:Interleukin-27 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000175:diagnosis; D055815:Young Adult
chemical_list: D064094:Interleukin-27
keywords: autoimmune disorders; interleukin-27 (IL-27); multiple sclerosis (MS); neuroinflammatory diseases